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desensitization procedure which we to date have not been able 
to explore in clinical practice. Clearly, there is a need for reliable, 
preferably in vitro diagnostics in order to properly establish the 
diagnosis and to better understand the underlying immunological 
mechanism of procarbazine-related DHR. Furthermore, prospec-
tive clinical trials comparing drug rechallenge via desensitization or 
treating through strategies in patients with mild-to-moderate DHR 
would facilitate optimal clinical decision-making regarding poten-
tial drug reintroduction.
In conclusion, desensitization or reintroduction of procarbazine 
appears to be feasible and safe in patients with mild-to-moderate 
cutaneous DHR to procarbazine; additional studies in larger patient 
populations are required in order to make robust recommendations 
regarding the exact safety profile.
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For hazelnut allergy, component testing of Cor a 9 and Cor a 14 
is relevant also in birch-endemic areas
To the Editor,
Diagnosis of nut allergy is usually based on history with a rel-
evant sensitization to the allergen in question and confirmed 
by allergen challenge. The diagnosis of hazelnut allergy in birch 
pollen-allergic patients is hampered by cross-reactivity from 
bich pollen.1,2 Earlier studies have concluded that Cor a 9 and 
14 are the most accurate components for hazelnut allergy 
diagnostics.3–5
DOI: 10.1111/all.14430 
Trial Registration: clinicaltrials.gov: NCT01502878  
Abbreviations: AUC, area under the curve; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value; ROC, receiver operating characteristic; SPT, skin prick 
test.
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Avoidance of hazelnut and a fear of an allergic reaction may af-
fect the quality of life, therefore improved in vitro diagnosis and in 
the case of a negative challenge, reintroduction of hazelnuts into the 
diet is the goal.
The aim was to study component diagnostics for severe hazel-
nut allergy in children and adolescents in a region with heavy birch 
pollination. Further, we assessed the success of reintroduction in pa-
tients with a negative challenge.
Eighty-two children and adolescents (aged 1–19 years) with sus-
pected hazelnut allergy were recruited at the Helsinki University 
Skin and Allergy Hospital. Eligible patients were sensitized to ha-
zelnut  (SPT ≥ 3 mm with ground unpeeled nut or  IgE ≥ 0.35 kU/L 
ImmunoCAP whole hazelnut).
Specific IgE was measured against whole hazelnut extract; Cor 
a 1 (PR-10 protein), 8 (lipid transfer protein), 9 (11 S globulin), and 
14 (2S albumin); and birch pollen extract. Skin prick tests were 
performed with ground hazelnut mixed with 0.9% saline and birch 
pollen extract.
At the double-blind placebo-controlled challenges (n = 56), on 
two days, each patient received 5, 50, 200, and 540 mg hazelnut 
protein, or placebo (Cumulative dose 795 mg, 6 hazelnuts). At open 
challenges (n = 26), doses were 5, 25, 50, 100, and 500 mg (Cumulat. 
680 mg). Reaction severity was assessed by a threshold-adjusted 
score in Table S1. A questionnaire of hazelnut reintroduction was 
sent to the challenge-negative patients.
The study (326/13/03/03/2010) was approved by the eth-
ics committee at the Helsinki University Hospital of Children and 
Adolescents.  One  of  the  parents  and  the  patient  (≥6  years  old) 
signed written informed consents. See details on methods in the 
supplemental text.
Of the 82 patients, 33 (40%) showed reaction to hazelnut. Of 
the challenge reactions, 6 (18%) were severe, 7 (21%) moderate, and 
20 (61%) mild. Four patients received adrenaline, and three of them 
needed more than one dose of adrenaline (2 to 3).
Birch pollen sensitization (SPT and/or IgE) was present in 68 
(83%) patients (sIgE ≥ 0.35 kU/L and/or SPT ≥ 3 mm) (median sIgE 
TA B L E  1   Baseline clinical characteristics and baseline values of the study population by challenge outcome
Challenge negative or mild 
(n = 69)
Challenge moderate or severe 
(n = 13) P value
Gender, female, n (%) 32 (46) 4 (31) 0.37
Age, mean (range) 9.7 (1.9-18.5) 10.1 (5.8-17.4) 0.70
Atopic dermatitis, n (%) 51 (74) 8 (62) 0.50
Asthma, n (%) 34 (49) 5 (39) 0.55
Other food allergy except nuts, n (%) 38 (55) 4 (31) 0.14
Previous history of reacting to some nut, n (%) 46 (67) 9 (69) 0.86
Birch pollen-allergic rhinitis 52 (77%) 6 (46%) 0.03
Serum total IgE kU/La  490 (17-14830) 346 (56-1225) 0.21
Hazelnut IgE kU/Lb  18.5 (0.3-470) 30.9 (0.4-521) 0.58
Hazelnut skin prick wheal size mmc  6 (0-18) 9 (0-16) 0.02
Birch pollen IgE kU/Lb  43.3 (0.03-918) 4.52 (0.02-542) 0.050
Birch pollen skin prick wheal size mmd  5 (0-13) 4 (0-13) 0.10
Blood eosinophil count E9/ld  0.39 (0.08-2.28) 0.27 (0.16-1.39) 0.75
Blood eosinophil percentaged  6 (1-29) 5 (3-16) 0.71
IgE to Cor a 1 kU/Le  19.1 (0-481) 4.74 (0-230) 0.050
IgE to Cor a 8 kU/La  0.03 (0-6.4) 0.02 (0-0.24) 0.27
IgE to Cor a 9 kU/L 0.21 (0-27.4) 1 (0.07-251) 0.001
IgE to Cor a 14 kU/L 0.04 (0-10.5) 6.3 (0-126) <0.001
Sensitization to Cor a 9 and
Cor a 14, n (%)
5 (7) 8 (62) <0.0001
Sensitization to Cor a 14 without Cor a 9, n (%) 7 (10) 1 (8) 1
Sensitization to Cor a 9 without Cor a 14, n (%) 25 (36) 4 (31) 0.76
No sensitization to Cor a 9 or Cor a 14, n (%) 32 (46) 0 0.001
Cor a 1 monosensitization 27 (39%) 0 0.008
Cor a 8 positive 9 (13%) 0 0.34
Note: Significant P value < 0.05 is calculated by Pearson chi-square, Fisher's exact, t test,or Mann-Whitney U test. Values are represented as medians 
(range) unless specified. Significant P values in bold. Sensitization is defined as IgE ≥ 0.35 kU/L. Number of available results.
an = 75 bn = 78, cn = 80, dn = 76, en = 74, fn = 79. 
     |  2979LETTERS TO THE EDITOR
33.8 kU/L [range 0-918], SPT 5 mm [0-13]; Table 1). Correlations 
between sIgE and SPT to hazelnut, Cor a 1, and birch pollen were 
moderate to strong (Table S2).
Although the challenge result correlated to some extent with IgE 
to whole hazelnut extract, moderate-to-severe hazelnut allergy could 
be most sensitively diagnosed by measuring IgE to both Cor a 9 and 
14 (Figure 1; Table 1). Higher levels of specific IgE to Cor a 9 and 14 
predicted lower eliciting dose at the challenge: Spearman's rho −0.514, 
P =  .002; and −0.413, P = .017, respectively. Cor a 14 was superior 
to Cor a 9 in predicting moderate-to-severe reaction (Figure 1). For 
the cutoff of 2.04 kU/L, the likelihood ratio was 15.9 and the positive 
predictive value was 75%. Cor a 9 sensitization without Cor a 14 was 
present in 29 (35%) patients, of whom 25 (86%) were tolerant at the 
challenge. By combining the IgE levels of Cor a 9 and 14, diagnostic per-
formance was equally good as with Cor a 14 alone (Figure 1; Table 1).
Fourty-seven of the 49 challenge-negative patients responded 
to the questionnaire on reintroduction of hazelnut. Of the respon-
dents, 18 (38%) had introduced hazelnut to their diet (full intro-
duction), 24 (51%) had not actively introduced, but reported not 
specifically avoiding hazelnut (partial introduction), and 5 (11%) re-
ported avoiding hazelnut carefully (no introduction).
This study suggests that asymptomatic sensitization to hazelnut 
is common and testing for whole extract specific IgE is not a reli-
able tool when evaluating suspected hazelnut allergy in an area with 
heavy birch pollination.
Serum IgE to whole hazelnut extract and Cor a 1 associate with 
diagnostic markers of birch pollen allergy rather than hazelnut 
allergy. Even high IgE to whole hazelnut can be explained by 
cross-reactivity from birch pollen. In this study, patients with high 
whole hazelnut IgE—up to 400 kU/L—without concurrent storage 
protein sensitization tolerated hazelnut. All Cor a 1 monosensi-
tized patients were asymptomatic or experienced only mild oral 
allergy symptoms. That specific IgE to whole hazelnut correlated 
strongly with Cor a 1, can be explained by the fact that hazelnut 
IgE ImmunoCAP is spiked with Cor a 1.6 Therefore, in a birch-en-
demic region, high serum specific IgE concentration to hazelnut 
is most often caused by cross-reactivity from birch pollen. The 
association of Cor a 1 sensitization and oral allergy syndrome is 
in line with studies from Central Europe and birch-endemic areas 
from the United States.3,4,7 Obviously, measuring Cor a 1 adds no 
value to the diagnosis of hazelnut allergy.
Studies from regions with less birch pollen exposure have 
reported Cor a 14-IgE as the best diagnostic marker for ha-
zelnut allergy. Our results and the cutoff of 2.04 kU/L are 
in agreement with these reports.8,9 However, the diagnos-
tic performance of Cor a 14-IgE was superior to Cor a 9-IgE, 
which is in line with most previous studies including children 
and adults both from regions with and without birch pollina-
tion.5,7–10 In our patients, sensitization to Cor a 9, without Cor 
a 14-sensitization, resulted in moderate-to-severe symptoms 
only in rare cases. By negative IgE testing for Cor a 9 and Cor 
a 14, true hazelnut allergy can be most accurately ruled out. 
In patients with a history of birch pollen allergy or sensiti-
zation to birch pollen, hazelnut sensitization is frequent due 
F I G U R E  1   Receiver operating 
characteristic (ROC) analysis of IgE to 
(A) whole hazelnut, Cor a 1, Cor a 8, 
and (b and c) Cor a 9, Cor a 14, and sum 
of IgE to Cor a 9 and 14 to discriminate 
negative and mild from the moderate and 
severe challenge reactions. CI, confidence 
interval; PPV, positive predictive value; 












































































Cor a 9 0.789 .001 0.67 0.91 0.64 77 71 2.7 33 94
Cor a 14
0.860          <.001         0.76        0.96           
0.848 <.001 0.70 0.99 2.04 69 96 15.9 75 94
Cor a 9 0.35 92 57 2.1 29 98
Cor a 14 0.35 69 83 4.0 43 93
Cor a 9 6.27 39 96 8.8 63 89
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to cross-reactivity (PR-10 proteins). Sensitization to hazelnut 
or Cor a 1 is a poor discriminator for hazelnut allergy in this 
group. This study, however, showed that Cor a 14 and, to a 
lesser extent, Cor a 9 were a good predictor for true hazelnut 
allergy. The combination of Cor a 9 and 14 improves allergenic 
risk assessment.
A follow-up on challenges showed that most patients were re-
assured by a negative challenge and discontinued the unnecessary 
avoidance of hazelnut.
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